Drug Trial News

RSS

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

27 Apr 2020

Researchers report promising Phase 1 results for first oral polio vaccine in 50 years

Before being halted due to the COVID-19 pandemic, a relentless vaccination campaign had nearly succeeded in eradicating polio from the world.

24 Apr 2020

First COVID-19-related clinical trial to start in Germany

German regulators have approved the first clinical trial of a coronavirus vaccine. Developed by BioNTech SE, an immunotherapy company, and Pfizer, a pharmaceutical company, the potential coronavirus vaccine has completed pre-clinical studies in Germany.

24 Apr 2020

Fewer kids enroll in pediatric oncology clinical trials, study shows

Historically, pediatric cancer patients have been much more likely than adult cancer patients to enroll in clinical trials as part of their treatment.

23 Apr 2020

New clinical trial to test two drugs for prophylactic treatment of COVID-19 contact persons

With the stepwise easing of measures in Switzerland, it is pivotal to monitor for any new COVID-19 outbreaks and to contain them in a timely and effective manner.

23 Apr 2020

A first-in-human trial with promising MERS coronavirus vaccine

Over the past 20 years, coronaviruses have been responsible for large outbreaks, resulting in severe respiratory illness and a number of deaths.

22 Apr 2020

Many phase II trials overestimate drug efficacy, pose a barrier in drug licensing

Based on a systematic analysis of trials related to rheumatoid arthritis and psoriasis arthritis, a MedUni Vienna study group at the Division of Rheumatology at MedUni Vienna/Vienna General Hospital was able to show that many clinical phase II trials systematically overestimate the efficacy of therapeutics, so that the results of subsequent phase III trials can often be disappointing. Essentially this situation also applies in many other areas.

21 Apr 2020

HIV-1 and influenza antivirals not effective for treating mild-to-moderate COVID-19 cases

An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol--antivirals that are used in some countries against HIV-1 and to treat influenza , respectively--as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.

20 Apr 2020

Penn Medicine launches convalescent plasma therapy trial for COVID-19 patients

Convalescent plasma therapy for COVID-19 patients -- an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection -- is the focus of a new two-part research initiative at Penn Medicine.

20 Apr 2020

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

A team of scientists at the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health, has tested the efficacy of remdesivir, a nucleotide analog prodrug with a broad antiviral activity, as a COVID-19 treatment.

20 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

Hydroxychloroquine and azithromycin treatment in 80 COVID-19 patients: short-term outcomes

The COVID-19 pandemic is still spreading around the world and affecting nearly 2.4 million people, with over 164,000 dead so far. With neither vaccine nor proven therapeutic drug being available so far, the need of the hour is for effective treatment. Now, a new study reports the potential usefulness of a combination of hydroxychloroquine and azithromycin as a treatment in mild cases of COVID-19 infection and urges the need for further evaluation and widespread use if its findings are confirmed.

19 Apr 2020

Gimsilumab trial starts in first US patient with ARDS and COVID-19

The first American patient with COVID-19 and acute respiratory distress syndrome (ARDS) has been put on the drug gimsilumab at Temple University Hospital, as part of the BREATHE clinical trial. The trial, sponsored by Roivant Sciences, will evaluate the effectiveness of intravenous gimsilumab in preventing death in patients with COVID-19 and ARDS.

16 Apr 2020

Gold-containing drug auranofin kills 95% of SARS-CoV-2 virus in 48 hours in lab conditions

A drug called auranofin, approved for the treatment of rheumatoid arthritis, effectively inhibits severe acute respiratory syndrome coronavirus (SARS-CoV-2) in laboratory conditions, as described in a new study by Georgia State University researchers.

16 Apr 2020

New antiviral drug reduces transmission of influenza, study shows

The antiviral drug, baloxavir (tradename Xofluza), is the first treatment for influenza with a new mode of "action" to be licensed in nearly 20 years.

16 Apr 2020

Octapharma USA supports new COVID-19 clinical trial

Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, M.D. of Sharp Memorial Hospital in San Diego, California focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator dependent.

16 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020

The race is on for a coronavirus vaccine, 70 candidates, 3 at human trial stage

Amid the coronavirus disease (COVID-19) global pandemic that is infecting millions of people across the globe, hope sparks as the World Health Organization (WHO) reports that seventy vaccination trials for the novel coronavirus are underway, with three already at the human trial stage.

14 Apr 2020

New vaccine for Chikungunya reported safe and well-tolerated

A virus-like particle vaccine was shown to be safe and well-tolerated among a healthy adult population living in chikungunya endemic areas, the researchers report in a new study published in the Journal of the American Medical Association (JAMA).

14 Apr 2020

Super-charging production of drugs for COVID-19

Researchers are ramping up production of a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures. The team hopes that the drug might also be effective in the fight against SARS's close genetic cousin, the novel coronavirus (COVID-19).

13 Apr 2020

Previous
1
...
80
81
82
83
84
85
86
...
1143
Next

Drug Trial News

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

Researchers report promising Phase 1 results for first oral polio vaccine in 50 years

First COVID-19-related clinical trial to start in Germany

Fewer kids enroll in pediatric oncology clinical trials, study shows

New clinical trial to test two drugs for prophylactic treatment of COVID-19 contact persons

A first-in-human trial with promising MERS coronavirus vaccine

Many phase II trials overestimate drug efficacy, pose a barrier in drug licensing

HIV-1 and influenza antivirals not effective for treating mild-to-moderate COVID-19 cases

Penn Medicine launches convalescent plasma therapy trial for COVID-19 patients

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

Hydroxychloroquine and azithromycin treatment in 80 COVID-19 patients: short-term outcomes

Gimsilumab trial starts in first US patient with ARDS and COVID-19

Gold-containing drug auranofin kills 95% of SARS-CoV-2 virus in 48 hours in lab conditions

New antiviral drug reduces transmission of influenza, study shows

Octapharma USA supports new COVID-19 clinical trial

Remdesivir drug stops novel coronavirus from replicating

The race is on for a coronavirus vaccine, 70 candidates, 3 at human trial stage

New vaccine for Chikungunya reported safe and well-tolerated

Super-charging production of drugs for COVID-19

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News